Boston scientific became aware of a patient experience post rezum procedure.The patient opted for rezum because it was a less invasive procedure.The patient underwent the procedure on november 22, 2021.The patient reports that it is past 3 months post procedure recovery period and is still experiencing incontinence and frequency symptoms.The patient has been on a series of antibiotics for urinary trat infection (uti) post procedure.In addition, the patient is taking meloxicam and vibegron and solifenacin (unknown dose) medications.The patient continued to experience leakage as well as frequency symptoms.Since the procedure the flow is much improve but the incontinence requires wearing a pad and shield.The patient expressed understanding of not seeing full improvement for three months; but did not expect to experience issues after three months.
|
Investigation summary based on the information available, there was no device available for analysis and there was no report of a device performance allegation during treatment.The reported patient symptoms are known risk associated with water vapor therapy procedures and are noted as such in the device instructions for use.Device history record (dhr) a dhr and ship history review cannot be performed as the lot number was not available.Device technical analysis the device is not available for analysis; therefore, no physical or visual analysis of the product could be performed.Labeling review a review of the device instructions for use (ifu) was completed and did not reveal any evidence of device misuse, off label use, or failure to follow instructions.Infection, urinary frequency, incontinence, urinary were found to be listed in the ifu.Investigation conclusion based on the information available, a conclusion code of known inherent risk of device was assigned to this investigation.
|